MFN2 and metabolic dysfunction-associated steatotic liver disease: One striking exception to this is the recent discovery that a point mutation in human mitofusin 2 (MFN2) produces profound adipose tissue dysfunction, non-alcoholic fatty liver disease, insulin resistance and type 2 diabetes [5–7].